Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLC

被引：0
|
作者：
Van Zandwijk, N [1 ]
Baas, P [1 ]
机构：
[1] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
来源：
TUMORI | 2002年
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [1] The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
    Wang, Fen
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 481 - 486
  • [2] Tyrosine kinase inhibitors as first-line treatment in NSCLC
    Maemondo, Makoto
    LANCET ONCOLOGY, 2016, 17 (05): : 541 - 543
  • [3] Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients
    Suryavanshi, M.
    Mattoo, S.
    Dhandha, S.
    Mehta, A.
    Batra, U.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1106 - S1107
  • [4] Tyrosine-kinase inhibitors—new standard for NSCLC therapy
    Nagahiro Saijo
    Nature Reviews Clinical Oncology, 2010, 7 : 618 - 619
  • [5] Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia
    Lomaia, Elza
    Zaritskey, Andrey
    Shuvaev, Vasily
    Martynkevich, Irina
    Fominykh, Mikhail
    Ovsyannikova, Ekaterina
    Lazorko, Natalia
    Matyuhina, Natalia
    Butylin, Pavel
    Machyulaitene, Elena
    Salamatova, Evgenia
    Abdulkadyrov, Kudrat
    BLOOD, 2015, 126 (23)
  • [6] Tyrosine-kinase inhibitors-new standard for NSCLC therapy
    Saijo, Nagahiro
    NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (11) : 618 - 619
  • [7] SIGNIFICANCE OF EUTOS AND HAMMERSMITH SCORE IN SECOND LINE TYROSINE KINASE INHIBITORS
    Zaritskey, A.
    Lomaia, E.
    Sbitiakova, E.
    Romanova, E.
    Ilina, N.
    Silina, T.
    Kulemina, O.
    Abdulkadyrova, A.
    Udalieva, V.
    Usacheva, E.
    Zotova, I.
    Golovchenko, R.
    Martynenko, L.
    Ivanova, M.
    Cybakova, N.
    Petrova, E.
    Kozlovskaya, M.
    Fominykh, M.
    Machiulaytene, E.
    Shuvaev, V.
    Martynkevich, I.
    Abdulkadyrov
    HAEMATOLOGICA, 2013, 98 : 558 - 559
  • [8] Development of the Third Generation EGFR Tyrosine Kinase Inhibitors for Anticancer Therapy
    Cheng, Weiyan
    Zhou, Jianhua
    Tian, Xin
    Zhang, Xiaojian
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (29) : 3343 - 3359
  • [9] Second or third-line chemotherapy in NSCLC
    Sorensen, JB
    PROCEEDINGS OF THE 9TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2004, : 69 - 75
  • [10] Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia
    Jorge Enrique Machado-Alba
    Manuel Enrique Machado-Duque
    International Journal of Clinical Pharmacy, 2017, 39 : 851 - 859
12345